Search PubMed⌕ Search

Biomedical subjects

Helga Hansdóttir

Publications and source records attributed to Helga Hansdóttir.

2 recordsLinked to original sources

[Dialogs on death].

OBJECTIVE: This study is done to examine the ideas of elderly individuals on life, death and end-of-life treatment in order to understand how they interact and influence choices of treatment. DESIGN: A phenomenological study. Eight Icelandic individuals 70 years old or more were interviewed in their homes. The interviews were open with two main questions. A special emphasis was on views toward life and death as studies have indicated their importance. RESULTS: All participants had a history of a good life despite experiences of death and loss. Enjoyment of life was evident along with an accepting attitude towards death. Everyone agreed on the necessity to limit life prolongation if there was no hope of recovery, much suffering, mental and physical ability compromised, no possibility of living a good life and being a burden to others. The participants based their attitudes toward end-of-life treatment on the likely outcome; evaluation of their own life; the impact on loved ones and experience of loss, grief and death. DISCUSSION: A model of end-of-life discussion between a physician and a patient is presented: The discussion takes place within an ethical and cultural framework, which is sometimes discussed. Physicians give information on diagnosis, prognosis, treatment options and the likely outcome. The patient evaluates the information in view of his/her own life based on age, health and views on life and death. The patient considers the impact of the decision made on loved ones and evaluates own experiences and that of others. Each factor has a negative and a positive side towards treatment. The decision on treatment is then made collectively. CONCLUSION: Discussion on end of life treatment involves following themes: Ethical, medical, the patients' evaluation of his/her own life, the impact of the decision on loved ones and experiences of loss, grief and death.

Age Factors↗

The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.

OBJECTIVES: To examine the effect of raloxifene on bone turnover in elderly women. DESIGN: Clinical intervention. SETTING: Long-term care facilities. PARTICIPANTS: Nineteen women completed the study, mean age 85 (range 76-99). INTERVENTION: Raloxifene 60 mg was given daily for 12 weeks. MEASUREMENTS: Markers of bone turnover were plasma C-telopeptides of type I collagen (CTx), urine cross-linked N-telopeptides of type I collagen (NTx) and serum tartrate-resistant acid phosphatase (TRAP 5b), plasma osteocalcin, and serum bone alkaline phosphatase. Other markers were serum 25-OH vitamin D, parathyroid hormone, ionized calcium, and phosphate. Markers were measured at baseline, after calcium and vitamin D had been taken for 6 weeks, after raloxifene had been taken for 12 weeks, and 6 weeks after raloxifene had been stopped. Paired sample t test was used to examine changes in markers at each time point. RESULTS: Plasma CTx decreased on average by 31%, urinary NTx by 35%, plasma osteocalcin by 25%, serum bone alkaline phosphatase by 15% (P<.01), and serum TRAP 5b by 10% (P<.05) on treatment. CONCLUSION: Raloxifene reduces bone turnover in elderly women living in long-term care facilities. The effect of raloxifene on bone turnover is comparable with that seen in younger postmenopausal women.

Acid Phosphatase↗